ArticleiScience2026
A palmitoylation signature for prognosis immune infiltration and drug sensitivity in esophageal carcinoma.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal carcinoma (ESCA) has a poor prognosis. This study aimed to develop a palmitoylation-related signature (PRS) for ESCA prognosis and therapy prediction. Using scRNA-seq and bulk RNA-seq data from public databases, we constructed a signature via Cox and LASSO regression. It was validated internally and externally. Associations with clinical features, immune infiltration, tumor mutational burden (TMB), and drug sensitivity were analyzed. A 7-gene PRS was established, stratifying patients into risk groups with distinct outcomes (1-3 years AUCs: 0.698-0.805). High-risk patients showed altered immune infiltration, TMB, and drug sensitivity. The gene PAH was highly expressed in ESCA and promoted proliferation, migration, and invasion via PI3K/AKT pathway activation. Furthermore, this tumorigenic effect depends on its palmitoylation modification. In conclusion, the PRS can serve as an independent prognostic biomarker for ESCA, effectively predict prognosis and treatment response, and may represent a potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.